Slowing remdesivir sales, plans on oncology in focus for Gilead Q1 earnings | Seeking Alpha

Retrieved on: 2022-04-27 18:05:05

Tags for this article:

Click the tags to see associated articles and topics

Slowing remdesivir sales, plans on oncology in focus for Gilead Q1 earnings | Seeking Alpha. View article details on hiswai:

Excerpt

Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. ... due to a decline in sales of the company's COVID-19 therapy Veklury (remdesivir).

Article found on: seekingalpha.com